John Martinez - IShares Pharmaceuticals Independent Trustee
| IHE Etf | USD 65.91 0.55 0.84% |
Mr. John E. Martinez serves as an Independent Trustee of Ishares Dow Jones US Pharmaceuticals Index Fund. Mr. Martinez has served as a Director of iShares, Inc. since 2003 and a Director of iShares MSCI Russia Capped Index Fund, Inc. since 2010. Mr. Martinez is a Director of EquityRock, Inc., providing governance oversight and consulting services to this privately held firm that develops products and strategies for homeowners in managing the equity in their homes. Mr. Martinez previously served as Director of Barclays Global Investors UK Holdings, where he provided governance oversight representing BGIs shareholders through oversight of BGIs worldwide activities. Since 2003, he is a Director and Executive Committee Member for Larkin Street Youth Services, providing governance oversight and strategy development to an agency that provides emergency and transitional housing, health care, education, job and life skills training to homeless youth
| Age | 55 |
| Tenure | 22 years |
| Professional Marks | MBA |
| Issuer | iShares |
| Inception Date | 2006-05-01 |
| Benchmark | Dow Jones U.S. Select Pharmaceuticals Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 610.64 Million |
| Average Trading Valume | 79,088 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
John Martinez Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Martinez against IShares Pharmaceuticals etf is an integral part of due diligence when investing in IShares Pharmaceuticals. John Martinez insider activity provides valuable insight into whether IShares Pharmaceuticals is net buyers or sellers over its current business cycle. Note, IShares Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell IShares Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Martinez over three months ago Acquisition by John Martinez of tradable shares of Maximus subject to Rule 16b-3 |
Similar Fund Executives
| Showing other executives | One Year Return | ||
| Madhav Rajan | iShares Insurance ETF | 52 | |
| Eilleen Clavere | iShares Insurance ETF | 60 | |
| Robert Silver | iShares Insurance ETF | 57 | |
| John Kerrigan | iShares Healthcare ETF | 60 | |
| Robert Kapito | iShares Healthcare ETF | 62 | |
| Cecilia Herbert | iShares Insurance ETF | 67 | |
| Scott Zoltowski | SPDR SP Pharmaceuticals | 43 | |
| Chad Hallett | SPDR SP Pharmaceuticals | 46 | |
| Charles Hurty | iShares Healthcare ETF | 72 | |
| Robert Kapito | iShares Insurance ETF | 61 | |
| Mary Zeven | SPDR SP Pharmaceuticals | 51 | |
| John Clark | SPDR SP Pharmaceuticals | 45 | |
| Matthew Flaherty | SPDR SP Pharmaceuticals | 41 | |
| Kevin Gustafson | Invesco Dynamic Pharmaceuticals | 42 | |
| Cecilia Herbert | iShares Healthcare ETF | 67 | |
| Ronn Bagge | Invesco Dynamic Pharmaceuticals | 54 | |
| Eilleen Clavere | iShares Healthcare ETF | 60 | |
| Helen Peters | SPDR SP Pharmaceuticals | 71 | |
| Dave Kelly | SPDR SP Pharmaceuticals | N/A | |
| Charles Hurty | iShares Insurance ETF | 72 | |
| John Kerrigan | iShares Insurance ETF | 60 | |
iShares Pharmaceuticals Money Managers
| Geoffrey Flynn, Chief Operating Officer, Executive Vice President | ||
| Robert Silver, Independent Trustee | ||
| John Kerrigan, Independent Trustee | ||
| Madhav Rajan, Independent Trustee | ||
| Matt Tucker, Vice President | ||
| Cecilia Herbert, Independent Trustee | ||
| Michael Latham, President Trustee | ||
| Jack Gee, Chief Financial Officer, Treasurer | ||
| Charles Hurty, Independent Trustee | ||
| Eilleen Clavere, Secretary | ||
| George Parker, Independent Chairman of the Board of Trustees | ||
| John Martinez, Independent Trustee | ||
| Amy Schioldager, Executive Vice President | ||
| Robert Kapito, Trustee | ||
| Ira Shapiro, Vice President Chief Legal Officer |
IShares Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is IShares Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 22.36 X | |||
| Price To Book | 1.56 X | |||
| Price To Sales | 3.32 X | |||
| Number Of Employees | 15 | |||
| Beta | 0.59 | |||
| Total Asset | 381.08 M | |||
| One Year Return | 6.50 % | |||
| Three Year Return | 1.60 % | |||
| Five Year Return | 6.10 % | |||
| Ten Year Return | 4.20 % |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Pharmaceuticals ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
The market value of iShares Pharmaceuticals is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is IShares Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Pharmaceuticals' market value can be influenced by many factors that don't directly affect IShares Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.